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Background: To assess differences between four different voxel-based dosimetry
methods (VBDM) for tumor, liver, and lung absorbed doses following 90Y microsphere
selective internal radiation therapy (SIRT) based on 90Y bremsstrahlung SPECT/CT, a
secondary objective was to estimate the sensitivity of liver and lung absorbed doses
due to differences in organ segmentation near the liver-lung interface.
Methods: Investigated VBDM were Monte Carlo (MC), soft-tissue kernel with density
correction (SKD), soft-tissue kernel (SK), and local deposition (LD). Seventeen SIRT cases
were analyzed. Mean absorbed doses (AD) were calculated for tumor, non-tumoral
liver (NL), and right lung (RL). Simulations with various SPECT spatial resolutions
(FHWMs) and multiple lung shunt fractions (LSs) estimated the accuracy of VBDM
at the liver-lung interface. Sensitivity of patient RL and NL AD on segmentation
near the interface was assessed by excluding portions near the interface.
Results: SKD, SK, and LD were within 5 % of MC for tumor and NL AD. LD and
SKD overestimated RL AD compared to MC on average by 17 and 20 %,
respectively; SK underestimated RL AD on average by −60 %. Simulations
(20 mm FWHM, 20 % LS) showed that SKD, LD, and MC were within 10 % of
the truth deep (>39 mm) in the lung; SK significantly underestimated the
absorbed dose deep in the lung by approximately −70 %. All VBDM were within
10 % of truth deep (>12 mm) in the liver. Excluding 1, 2, and 3 cm of RL near
the interface changed the resulting RL AD by −22, −38, and −48 %, respectively,
for all VBDM. An average change of −7 % in the NL AD was realized when
excluding 3 cm of NL from the interface.
Conclusions: SKD, SK, and LD are equivalent to MC for tumor and NL AD.
SK underestimates RL AD relative to MC whereas LD and SKD overestimate.
RL AD is strongly influenced by the liver-lung interface.
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Liver-directed selective internal radiation therapy (SIRT) has experienced clinical
growth in recent years for the management of both hepatocellular carcinomas
and metastatic disease from colorectal cancer, breast cancer, and neuro-2015 Mikell et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
riginal work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
ublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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on body surface area and the assumption that activity is distributed uniformly
throughout the liver, while the absorbed dose to the lung is based on the lung
shunt fraction (LS) [1, 2]. A major limitation of these models is that they do not
separate tumors from non-tumoral liver (NL) and are more accurately character-
ized as “safety planning” methods rather than “treatment planning.” The partition
model [3] offers an improvement in that it separates tumors from NL, but it sim-
plistically models all tumors as a single entity having a singular uptake fraction
and assumes uniform activity distribution throughout the tumor and NL
compartments.
Recent progress in post-therapy quantitative 90Y imaging with SPECT/CT and posi-
tron emission tomography/CT has facilitated voxel-level absorbed dose calculations.
Voxel-based absorbed dose calculations are affected by the 90Y image quality in terms
of quantitative accuracy and spatial resolution. Unlike other models, voxel-based
absorbed dose calculations do not require tumor burden, tumor segmentation, or tumor
uptake fraction as inputs for estimating absorbed dose at each voxel. Organ-at-risk and
tumor segmentation are still necessary in voxel-based dosimetry, but segmentation is per-
formed to report on the calculated absorbed doses and not to explicitly calculate the
absorbed dose. Voxel-based dosimetry methods (VBDM) allow the absorbed dose calcula-
tion to be independent of the tumor and organ-at-risk segmentation.
There are several methods to calculate voxel-based absorbed doses for SIRT. How-
ever, little has been published in the literature comparing different VBDM, and the
comparisons have been confined to the liver [4]. Lung dosimetry is of importance for
SIRT because absorbed dose to the lung often limits the deliverable activity. The lung
shunt fraction is estimated using 99mTc-macroaggregated albumin (MAA) with planar
(or sometimes SPECT) imaging [5, 6]. In some instances, 99mTc-MAA SPECT/CT is
performed to assess extra-hepatic uptake and these can in principle be used for therapy
planning [7]. 99mTc-MAA SPECT scans have superior image quality compared to
post-therapy bremsstrahlung 90Y SPECT scans, but there are studies showing MAA
does not reliably predict the distribution of delivered 90Y microspheres [8]. To our
knowledge, no previous study has reported the use of VBDM for determining absorbed
dose to the lung and explored the implications of different VBDM in the liver-lung
interface region [9, 10]. Both the EANM [5] and AAPM [6] provide guidance for clin-
ical standard of practice 90Y microsphere therapy, but neither document addresses the
effect of different VBDM which are under investigation.
In this study, we investigated differences among four VBDM for tumor, liver, and
lung absorbed doses based on 90Y bremsstrahlung SPECT/CT imaging. Accuracy of the
different methods at the liver-lung interface was estimated for different spatial resolu-
tions and LS. Patient data was analyzed to determine the sensitivity of NL, right lung
(RL), and total liver AD to the liver-lung interface.Methods
Patient data
Patient data was processed to assess the impact of the different VBDM on absorbed
dose calculations under realistic clinical situations. Accurate comparisons between
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activity and SPECT/CT images) into all of the VBDM. A total of 17 post-therapy 90Y
SPECT/CT were selected for this study using a UT MD Anderson Cancer Center Insti-
tutional Review Board-approved retrospective chart review protocol where the in-
formed consent requirement was waived. The mean administered activity was 2.81 ±
1.04 GBq (range 1.13–5.21 GBq). The administered activities were based on the
package insert for the treatment device: ~120 Gy to treatment volume for glass mi-
crospheres. Adjustments were made to the activity based on the lung shunt fraction
that was estimated by the 99mTc-MAA scans. Diagnostic CT or magnetic resonance
images were manually registered to the SPECT/CT to aid in tumor delineation. A
single interventional radiologist segmented the liver and tumors for all patients
using the co-registered CT and/or magnetic resonance images. NL was generated by
subtracting the tumor contours from the liver contour. RL was segmented using re-
gion growing in MIM Maestro v6.2 (MIM Software); RL was then inspected and
manually adjusted by a physicist.
The 90Y SPECT/CT scans were acquired on a Symbia T16 (Siemens Medical Solutions)
with medium-energy low-penetration collimation. SPECT data were acquired with a
90–125 keV primary window and 312–413 keV scatter window for 128 views over 360° with
28 s/view. A three-dimensional (3D) ordered-subset expectation maximization (Flash3D,
Siemens Medical Solutions) SPECT reconstruction was performed using 4 iterations and 8
subsets with a 9.6 mm FWHM Gaussian post-filtering. The reconstructed isotropic voxel
size was 4.8 mm. The reconstruction modeled geometric collimator response, CT-based at-
tenuation correction using effective energy of the energy window width, and an energy
window-based scatter correction [11]. The spatial resolution of the reconstruction was
estimated to be 20 mm FWHM using an 90YCl2 line source in cold background.
Activity in each voxel (Aijk) was calculated by converting reconstructed SPECT counts to
activity through a self-calibration factor defined as Administered Activity/Total Counts. We
have assumed that all administered activities were within the SPECT field of view because
most of the lung was included in the SPECT field of view; no correction for LS was applied.
The Total Counts =∑Cijk where Cijk represents the reconstructed counts in a voxel and the
summation is over the entire SPECT volume.
Absorbed dose volume histograms of tumor, NL, and RL were generated for each pa-
tient and each VBDM. Correlations of AD from local deposition (LD), soft-tissue kernel
(SK), and soft-tissue kernel with density correction (SKD) with Monte Carlo (MC) were
investigated for tumor, NL, and RL. A qualitative evaluation of differences in the iso-
dose distributions was also performed.Voxel-based dosimetry methods investigated: MC, SKD, SK, and LD
Four VBDM were investigated to calculate voxel-based absorbed doses for SIRT: MC,
SKD, SK, and LD. MC was performed with the EGSnrc [12] user code DOSXYZnrc
[13]. All electrons and photons were tracked down to kinetic energies of 1 keV. The
simulation parameters included bound Compton scattering, Rayleigh scattering, atomic
relaxations, Beithe-Heiler bremsstrahlung cross sections, simple bremsstrahlung angu-
lar sampling, spin effects, exact boundary crossing, and PRESTA-II. Voxel-level mater-
ial (Mijk), activity (Aijk), and density (ρijk) distributions were derived from quantitative
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technique-specific linear lookup table based on electron density phantom scans. Mijk
was generated by mapping ρijk to one of four materials (air [14], lung [15], soft tissue
[16], or bone [15]) based on density ranges.
We assume that 90Y microspheres have no biological clearance, so the total number of
disintegrations in a voxel is given by Nijk ¼ Aijk ⋅ T 1=2ln 2ð Þ where T1/2 is the physical half-life of
90Y (64.1 h). 90Y β− has a maximum energy of 2.28 MeV corresponding to a maximum
range of 11 mm in soft tissue[17], but the range increases to 44 mm in the lung with density
0.26 g/cc.
Table 1 summarizes the different VBDM investigated in this work. Absorbed doses
calculated using MC are a function of material, total number of disintegrations,
density, and the energy spectra of the beta particle emitted. Patient MC simulations
were performed using 109 histories. LD requires only the average energy of the beta
particle and mass of each voxel. For SK and SKD, the absorbed dose soft tissue ker-
nel was generated from MC simulations in an infinite soft-tissue medium with dens-
ity of 1.04 g/cc using 2 × 109 histories; it was validated by comparing with
Lanconelli et al. [18]. The simulation yielded statistical uncertainty ≤0.002 % in the
source voxel and ≤2.5 % at 40 mm. The kernel had isotropic voxel size of 4.8 mm
matching the reconstructed SPECT. SK and SKD were calculated by convolving the
total number of disintegrations with the kernel; convolutions were performed in
IDL v8.2 (Exelis Visual Information Solutions). SKD was then scaled by the ratio of
kernel density to voxel density [4].Assessing sensitivity of NL, RL, and total liver mean absorbed to the liver-lung interface
To assess sensitivity of NL, RL, and total liver AD to the liver-lung interface in patient data,
we generated remainder VOI for total liver, NL, and RL by excluding regions extending 1, 2,
or 3 cm from the liver-lung interface into both the liver and lung. The sensitivity of AD on
segmentation was analyzed in Excel by plotting the AD to the original VOI as a function of
the AD to the remainder VOIs and fitting a line to the data. Figure 1 shows an example of
the remainder VOI generation.Simulation to estimate the impact of spatial resolution and LS on the accuracy of VBDM
at the liver-lung interface
Simulations were performed to estimate errors in the absorbed dose calculations
around the liver-lung interface for the different VBDM as a function of spatialTable 1 Characteristics of the different VBDM investigated
VBDM Functional form Notes
Monte Carlo (MC) F(Mijk, Nijk, ρijk, E90Y) E90Y is the beta energy spectra per disintegration
Local deposition (LD) Nijk⋅
Eavg
ρijk ⋅ΔV
Eavg(0.937 MeV) is the average energy of the beta particle per
disintegration. ΔV is the volume of a voxel.
Soft-tissue kernel (SK) Nijk⊗ Ki ' j ' k '
Ki ' j ' k ' is obtained from a MC simulation of infinite uniform





⋅ 1:04ρijk Assumes ρijk is in units of g/cc
⊗ denotes convolution
Fig. 1 Sagittal view through liver and RL illustrating excluded regions from the liver-lung interface.
Remainder RL (red), excluded RL (yellow), excluded liver (blue), and remainder liver (pink)
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LS; this simple simulation had two compartments (liver and lung) shown in Fig. 2
and does not use patient data. We placed a uniform amount of activity in the liver
compartment representing a true activity distribution. To simulate limited spatial reso-
lution, the activity in the liver was convolved with a Gaussian FWHM of 10 or 20 mm caus-
ing spill-out of the liver and spill-in to the lung. MC, SK, SKD, and LD voxel-level absorbedFig. 2 Schematic geometry of the simulations for the liver-lung interface with uniform activity in the slab
representing either the liver (a) or lung (b). Arbitrary LS were achieved through superposition of individual
VBDM for both liver and lung. Finite spatial resolution was modeled through Gaussian blurring. Data was
averaged in the orange region to generate 1D absorbed dose profiles along the dashed line
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were normalized to the input activity. A similar process was carried out for the lung.
The density of the soft tissue and lung was set to 1.04 [16] and 0.26 g/cc [15],
respectively. A newer ICRP report [19] lists the density of the lung as 0.25 g/cc,
but we do not expect results to change significantly due to a 0.01 g/cc difference
in density. The simulation volume consisted of 61 × 61 × 61 4.8 mm isotropic
voxels. These voxels were padded such that the total dimensions were 200 ×
200 × 200 cm3 approximating an infinite phantom. One-dimensional (1D) line
profiles along the z axis were generated by averaging the central 7 × 7 voxels in
each x-y plane.
For the three spatial resolutions, the liver and lung VBDM absorbed doses were
combined via superposition by weighting the lung component by LS and the liver
by 1-LS. We investigated LS of 1, 10, and 20 %. For quantitative comparison be-
tween VBDM, we defined the true absorbed dose distribution as the MC profile
of 0 mm FWHM for a given LS; specifically, distance intervals along the 1D pro-
file for which the different calculations agreed within ±10 % of the truth are
reported.Results
Comparing SKD, SK, and LD with MC for patients
Figure 3 illustrates the salient differences in the apparent absorbed dose distribution
stemming from the four VBDM; it shows the different absorbed dose calculations
throughout the RL and liver on a coronal CT slice for a patient. The isodose curves
deep within the liver were nearly identical for all four methods. The 20 Gy line ex-
tended furthest in the lung for SKD and LD followed by MC and then SK (least pene-
tration into lung). The LD isodose distribution was very similar to the SKD
distribution. There was an unequivocal qualitative difference in the lung absorbed dose
distribution when SK was compared with MC, LD, or SKD, owing to the fact that SK
assumes soft-tissue density of 1.04 g/cc regardless of the true density and material
composition.
The correlations in absorbed dose as estimated using LD, SK, and SKD in relation to
the true values from MC are shown in Fig. 4. All the correlations had R2 > 0.975. Slopes
of the fit lines ranged from 0.98 to 1.00 for tumors and NL. For RL AD, the slopes were
0.88, 0.90, and 2.32 for SKD, LD, and SK, respectively. The summary of percent differ-
ences relative to MC are listed in Table 2. AD to tumors and NL using LD, SK, and
SKD were within 5 % of MC . For AD to RL, LD had the best agreement (17 % on aver-
age) with MC, whereas SK had the poorest agreement (−60 % on average).Sensitivity of total liver, NL, and RL mean doses to the liver-lung interface
Figure 5 shows the MC AD to the RL when regions extending 1, 2, or 3 cm from the
liver-lung interface were excluded from both the liver and lung VOIs. The sensitivity
was similar for all VBDM. For total liver, the slopes were 0.94, 0.87, and 0.74 when ex-
cluding 1, 2, and 3 cm from the interface, respectively; NL was less sensitive with slopes
of 0.97, 0.94, and 0.92, respectively, and RL was the most sensitive with slopes of 1.43,
1.89, and 2.14, respectively. The RL AD sensitivity to the liver-lung interface was seen
Fig. 4 The correlation of patient absorbed doses from MC with those from LD (green triangles), SK (red
squares), and SKD (blue diamonds) for tumor AD (N = 31) (a), NL AD (N = 17) (b), and RL AD (N = 17) (c) shown
together with their linear fits. The gray dashed line represents the line of equivalence
Fig. 3 A coronal plane through the RL and liver illustrating salient differences between the four different
VBDM: MC (a), LD (b), SK (c), SKD (d). The tumor (shaded in cyan) is 5.2 cm in length in the
cranial-caudal direction
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Table 2 Percent differences in AD when using SKD, SK, and LD compared with MC
SKD vs. MC SK vs. MC LD vs. MC
Tumor AD
−0.2 % ± 0.3 %, 1.6 % ± 1.2 %, 0.9 % ± 1.2 %,
[−1.7 %, 0.0 %] [−2.6 %, 3.1 %] [−0.4 %, 4.7 %]
NL AD
−0.3 % ± 0.1 %, 1.5 % ± 0.7 %, −0.1 % ± 0.5 %,
[−0.5 %, −0.1 %] [−0.6 %, 2.3 %] [−1.3 %, 0.6 %]
RL AD
19.6 % ± 9.9 %, −60.2 % ± 3.7 %, 17.4 % ± 9.4 %,
[7.3 %, 48.3 %] [−65.8 %, −52.7 %] [6.5 %, 45.1 %]
μ ± σ, [min, max] of (100 × (calculation −MC)/MC)
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liver-lung interface for the total liver and NL resulted in average differences of 4.1 and
6.9 %, respectively, from the original AD to VOIs (without excluded regions), suggesting
relative insensitivity to the interface region. On the contrary, excluding up to 3 cm of
the interface for the RL led to an average difference of −48.4 % from the original AD ,
suggesting that RL AD is very sensitive to the interface region.Effect of spatial resolution and LS on accuracy of the VBDM at the liver-lung interface
Figure 6 shows the percent differences of the different absorbed dose calculations rela-
tive to the truth (MC of true activity distributions) for different LS and different
FWHM. LD is not displayed since the differences are similar to SKD. Errors on the
liver side of the interface were generally within 30 % and approached 0 as the blurring
decreased to 0 and moved away from the interface deeper into the liver. Near the lung
interface, errors for 20 mm FWHM blurring and 1 % LS were within 20 % when using
SK compared to errors over 200 % for MC and SKD. Table 3 lists the distance intervals
where agreement with MC was within 10 %; on the liver side, agreement to within
10 % for all methods was found beyond 4, 6, and 12 mm from the interface for 0, 10,Fig. 5 The MC AD to the patients’ RL (N = 17) when regions extending 1 (blue circle), 2 (red x), or 3 cm
(green pentagon) from the liver-lung interface were excluded from the original RL VOI shown together with
the linear fit. The gray dashed line represents the line of equivalence
Fig. 6 1D profiles from VBDM simulations with different spatial resolution (20 mm FWHM (blue), 10 mm
FWHM (red), 0 mm FWHM (orange)) at the liver-lung interface showing percentage differences from MC
without blurring. LD is omitted since it is similar to SKD. LS is 1 % in MC (a), SKD (b), and SK (c). LS is 20 %
in MC (d), SKD (e), and SK (f).
Table 3 Intervals in millimeters where the VBDM are accurate to within 10 % as a function of LS
and FWHM where positions ≤0 represents the liver, positions >0 represents the lung, and 0






1 (−∞, ∞ ) (−∞,−4) U (31,∞) (−∞,−12) U (39, ∞)
10 (−∞, ∞ ) (−∞, −3) U (−2, −1) U (17, ∞) (−∞ ,−11) U (−2,−1) U (26, ∞)
20 (−∞, ∞ ) (−∞, 0) U (11, ∞) (−∞, −10) U (−2,−1) U (21,∞ )
LD 1 (−∞, −4) U (−2,−1) U (26, ∞) (−∞,−4) U (−2,−1) U (7, 8) U(26, ∞) (−∞,−11) U (−2,−1) U (24, ∞)
10 (−∞, 0) U (11,∞) (−∞, −5) U (−2,−1) U (7, ∞) (−∞,−11) U (−2,−1) U (19, ∞)
20 (−∞, ∞) (−∞ ,−5) U (−2,−1) U (8,∞) (∞,−9) U (−2,−1) U (16, ∞ )
SKD 1 (−∞,−2) U (4,5) U (23,∞) (−∞,−6) U (−2,−1) U (10,11) U (23, ∞) (−∞, −11) U (−2,−1) U (29,∞)
10 (−∞, −1) U (6, ∞) (−∞,−6) U(−2,−1) U(11,∞) (−∞,−11) U (−2,−1) U (23,∞)
20 (−∞, −1) U (7,∞) (−∞, −6) U (−2,−1) U (11, ∞) (−∞,−10) U (−2,−1) U (21, ∞)
SK 1 (−∞, −2) (−∞, −6) (−∞, −11) U (−0.5, 2) U (9, 13)
10 (−∞, −2) (−∞, −6) (−∞, −11)
20 (−∞, −2) (−∞, −6) (−∞, −10)
The true absorbed dose distribution was MC with FHWM = 0. We employed interval notation (e.g., (x1, x2) ∪ (x3, x4)
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Mikell et al. EJNMMI Physics  (2015) 2:16 Page 10 of 14and 20 mm FWHM blurring, respectively, with a LS from 1 to 20 %. For MC, LD, and
SKD in the lung, agreement was found beyond 26, 31, and 39 mm for 0, 10, and
20 mm FWHM blurring, respectively.
SK approximated the true absorbed dose near the lung interface well for 1 % LS with
blurring of 10 and 20 mm but significantly underestimated the absorbed dose at the
lung interface and deep into the lung for the higher LS. MC matched the true lung
absorbed dose better for the higher LS and lower blurring. SKD and LD overestimated
near the lung interface compared to MC, but they both approached the true value deep
(>39 mm) within lung.
LD, SK, SKD, and MC approached the same value deep (>12 mm) within the liver,
and they were all similar on the liver side of the interface, with MC performing slightly
better than the others given a larger FWHM. On the liver side of the interface, LD, SK,
and SKD all underestimated the absorbed dose similarly when the activity distribution
was blurred.
Figure 7 provides context of the relative differences in Fig. 6 by showing line
profiles of absorbed dose in arbitrary units for the VBDM with different lung
shunt fractions and spatial resolutions. Figure 7 can be used to estimate absolute
errors in the absorbed dose near the interface. For example, if one assumes the
absorbed dose within the liver far from the interface is 80 Gy, then the SKDFig. 7 1D dose distributions at the liver-lung interface to compare the four VBDM for different
spatial resolution and LS. LS is 1 % in 0 mm FWHM (a), 10 mm FWHM (b), and 20 mm FWHM
(c) while LS is 20 % in 0 mm FWHM (d), 10 mm FWHM (e), and 20 mm FWHM (f). A.U.
arbitrary units
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20 mm would be ≈9.4E-15/1.1E-14 × 80 Gy ≈ 68 Gy whereas the true value would
be ≈1.9E-15/1.1E-14 × 80 Gy = 14 Gy.
Discussion
Our NL and tumor absorbed dose results are similar to those reported by Dieudonne
et al. [4]; both studies showed better agreement with MC when using SKD instead of
SK. Our work adds to the body of knowledge on 90Y dosimetry in part by assessing
absorbed dose differences in the patient data due to differences in methodology. We
also included LD voxel-based estimates in our comparison; these estimates are relevant
since investigators have recently begun using LD in voxel-based absorbed dose calcula-
tions following SIRT [20, 21]. Lung dosimetry is also of central importance in SIRT
because lung absorbed dose limits the administered activity of 90Y and can prevent patients
from receiving adequate therapeutic tumor absorbed doses. However, to date, no work has
compared VBDM for the lung and in the liver-lung interface based on 90Y bremsstrahlung
SPECT/CT imaging.
The correlations of LD, SK, and SKD with MC for mean absorbed dose to tumors,
NL, and RL could potentially be used to convert mean absorbed doses between the dif-
ferent VBDM for our image acquisition protocol.
The sensitivity of the patients’ RL, NL, and total liver AD to the liver-lung interface
agrees with the trend that larger distances from the interface are required in the lung
(relative to the liver) to reach accurate absorbed doses. The RL AD decreased by ~50 %
(8.8 ± 5.4 Gy to 4.2 ± 2.3 Gy) when 3 cm of the interface was excluded, whereas the
total liver AD only increased by ~3 % (45.1 ± 12.7 Gy to 46.6 ± 15.0 Gy) for a similar
interface exclusion. From a clinical perspective, this finding highlights that the liver AD
is not sensitive to the interface region, but RL AD is sensitive to the interface and the
community needs to establish standards and guidelines for lung segmentation to ensure
proper reporting of lung absorbed doses when using VBDM. These findings call for
careful consideration of lung dose based on post-therapy 90Y imaging (and to a lesser
degree pre-therapy 99mTc-MAA) for cumulative lung dose calculation as part of repeat
treatments where cumulative lung dose is not to exceed 50 Gy. Patient respiratory mo-
tion further degrades the effective spatial resolution at the liver-lung interface because
motion correction techniques are not available in commercial SPECT/CT systems.
The simulated estimates of accuracy for MC, LD, SK, and SKD around the liver-lung
interface as a function of LS and spatial resolution FWHM showed that all four VBDM
investigated are within 10 % of the true liver absorbed dose when deeper than 12 mm
from the liver-lung interface; this distance is expected to increase for larger FWHM
and lower LS. Using MC, LD, or SKD, a similar accuracy was achieved in the lung
when deeper than 39 mm from the interface. SK is not suitable for estimating accurate
deep lung absorbed doses, but in the special case where LS is small and FWHM is
large, SK may provide accurate estimates in close proximity to the liver-lung interface;
this transient accuracy occurs due to SK errors in lung dosimetry canceling errors due
to spill-in/out at the interface.
For the clinical results (tumors, NL, and RL), we have only investigated differences
among VBDM in this work. Although we estimated accuracy of VBDM at the liver-
Mikell et al. EJNMMI Physics  (2015) 2:16 Page 12 of 14lung interface through simulations, we have not performed such simulations for patient
data. Future work should include the use of virtual phantoms where the true activity
distribution is known followed by imaging simulation and application of VBDM to
estimate true accuracy of such methods in patients.
Some have argued that LD may be preferable to transport (SK, SKD, or MC) for
pure-beta emitters such as 90Y [22]; radiation transport spreads 90Y beta energy depos-
ition locally at ~5 mm scale in soft tissue. Their rationale is that the finite spatial
resolution of the imaging system (typically >10 mm in emission imaging) can account
for beta radiation transport. However, realistic particle transport will depend on tissue
type and density (e.g., soft tissue vs. lung). Although not discussed here, the collapsed
cone convolution is another VBDM that is accurate at the lung soft-tissue interface for
SIRT [23].
Our results on accuracy suggest that if one uses VBDM, then to reduce errors in
absorbed dose estimates at the interface, the effective spatial resolution (physical spatial
resolution and motion blurring) at the liver-lung interface should be minimized.
Improvements in SPECT image quality would provide improved voxel-based activity
distribution, especially at the liver-lung interface.
One limitation of our study stems from the use of a free-breathing CT scan as part of
SPECT/CT. Consequently, the contoured liver/lung interface could be from any point
of the respiratory cycle. In the analysis of the interface patient data, the results must be
viewed critically since there is not a straightforward method to determine the correct
spatial location or a reference volume for the lung. We have only estimated errors in
1D absorbed doses for misplaced activity at the lung-liver interface due to effective
spatial resolution, not the change in activity due to incorrect attenuation correction at
the interface. Future work could involve analysis with some respiratory motion man-
agement such as breath hold, average CT, or 4D-CT. There was also uncertainty in the
delineation of the tumor, liver, and lung and registration errors between the diagnostic
contrast examination and the attenuation scan on the SPECT. Our RL segmentation
methodology was similar to Busse et al. who reported that region growing resulted in
an average error of 7 % for lung mass estimates based on free-breathing CT scans of
the thorax [24]. We would like to point out that the patient data analysis was based on
a single SPECT/CT model and customized imaging protocol and segmentation by a
single physician using data from our institution.
There are limitations to all imaging acquisition and reconstruction protocols. Differ-
ences at the liver-lung interface depend on several parameters including spatial reso-
lution, respiratory motion, activity distribution near the interface, free-breathing CT vs
average CT vs breath-hold CT, and the corresponding scatter and attenuation compen-
sations during reconstruction. Consequently, the magnitude of the sensitivity of right
lung, total liver, and non-tumoral liver absorbed dose to the liver-lung interface may
change if PET/CT or a different SPECT/CT acquisition protocol or reconstruction al-
gorithm such as Rong et al. [25] is used. In this work, we have investigated differences
among four VBDM for tumor, liver, and lung absorbed doses based on a given 90Y
bremsstrahlung SPECT/CT imaging; the magnitude of the clinical findings in this work
may change with different acquisition or reconstruction protocols, but the trends in
sensitivity to the interface should hold. Thus, these findings are not restricted to any
one specific 90Y image generation technique.
Mikell et al. EJNMMI Physics  (2015) 2:16 Page 13 of 14SPECT calibration is important for reconstructing quantitative images. We estimated
the 95 % confidence interval in our self-calibration to be ~10 %, based on 25 different
patient scans. The purpose of this work was to investigate differences between VBDM,
and thus by design the administered activity and total SPECT counts were the same
between different VBDM. Therefore, the results of this work are not sensitive to the
uncertainties in SPECT self-calibration.Conclusions
Voxel-based dosimetry was performed using post-therapy 90Y bremsstrahlung SPECT/
CT. Multiple VBDM (MC, LD, SKD, SK) were investigated and compared to MC for
AD for tumor, NL, and RL. Differences were equivalent (<5 %) for tumor and NL AD ,
with SKD agreeing best with MC. Larger differences were found for the RL AD , with
LD agreeing best with MC and SK producing dramatically incorrect values deep in the
lung. Simulations of the liver-lung interface for multiple effective spatial resolutions
and LSs were used to estimate nominal distance from the liver-lung interface where
good accuracy was achieved deep within the liver and deep within the lung. Finite
spatial resolution was shown to cause RL AD estimates to be sensitive to the liver-lung
interface region.
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